

CanREValue Stakeholder consultation

Stakeholder input is essential to the development of a framework for the incorporation of real-world evidence for cancer drug decision-making. We encourage stakeholders to participate by answering the list of consultation questions provided for your consideration below, or to provide any other comments regarding the contents of the report.

To provide feedback and input on the interim Methods report, please use this feedback template. Please submit your completed feedback by 5:00pm EDT **on April 19th, 2020** to canrevalue@cc-arcc.ca.

Note: Feedback is limited to ~5 pages of text using 12pt font. All feedback will be collated and our subsequent responses to the feedback will be made publicly available.

Consultation Questions:

1. Are there other key biases present within population-based administrative data that must be considered in analyses of comparative effectiveness evaluating survival outcomes?
2. Are there additional methods that should be included to address the key biases identified when using population-based administrative data to evaluate comparative survival outcomes?
3. Are there specific questions related to the application of these methods that the final report / manuscript should address?

In addition, please consider:

4. Are there specific methodological questions with regard to the generation of RWE which you are interested in exploring in the future? For example, what types of methodological challenges do decision-makers face that RWE can address or what problems exist that decision-makers would like RWE to help solve?

The CanREValue Methods Working Group is also working on a manuscript to provide an overview with more details on methods to analyze real-world survival data. Please contact us at canrevalue@cc-arcc.ca if you would like more information about this work.

